Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2019-06-03, Stock:NVS, The news for the past five days is as follows:
2019-05-24: NEWS1: Approval of a Game-Changing Gene Therapy for SMA Delivers a Win for Novartis and Regenxbio.NEWS2: For Anderson family, an early bet on SMA gene therapy.NEWS3: Novartis $2 million gene therapy for rare disorder is world's most expensive drug.NEWS4: Novartis $2 mln gene therapy for rare disorder is world's most expensive drug.NEWS5: At $2M, priciest ever medicine treats fatal genetic disease.NEWS6: At $2M, priciest ever medicine treats fatal genetic disease.NEWS7: For Anderson family, an early bet on SMA gene therapy.NEWS8: Novartis gets FDA nod for advanced breast-cancer treatment.NEWS9: Novartis' breast cancer treatment wins FDA approval.NEWS10: FDA approves $2M medicine, most expensive ever.NEWS11: 4 Top Stock Trades for Tuesday: ROKU, ADSK, SPLK, NVS.NEWS12: Novartis' breast cancer treatment wins FDA approval.NEWS13: No Miracle Drug Should Cost $2.1 Million.NEWS14: FDA approves Novartis gene therapy for rare genetic disorder.NEWS15: Novartis Gene Therapy To Cost $2.13 Million, Rivaling Biogen, Ionis.NEWS16: The Funded: One Bay Area biotech goes public while another files IPO plans.NEWS17: FDA okays $2M medicine, most expensive ever.NEWS18: Biogen loses edge on blockbuster rare disease market with Novartis' FDA approval.NEWS19: AveXis receives FDA approval for Zolgensma®, the first and only gene therapy for pediatric patients with spinal muscular atrophy (SMA).NEWS20: FDA approves Novartis' $2.1 million gene therapy — making it the world's most expensive drug.NEWS21: FDA approves Novartis' $2 million gene therapy for spinal muscular atrophy.NEWS22: Novartis Gains FDA Approval For Gene Therapy Rivaling Biogen, Ionis.NEWS23: U.S. approves Novartis gene therapy for rare, deadly muscle disorder.NEWS24: Highlights from CNBC&apos;s Healthy Returns conference.NEWS25: Highlights from CNBC's Healthy Returns conference.NEWS26: Pharma Stock Roundup: MRK's Cancer Biotech Buyout, ABBV, LLY's Pipeline Updates.NEWS27: Novartis wins approval for world’s most expensive drug.
2019-05-28: NEWS1: Conatus Down More Than 60% in the Past 90 Days: Here's Why.NEWS2: Conatus Down More Than 60% in the Past 90 Days: Here's Why.NEWS3: FDA approves most expensive gene therapy ever — and here is its connection to Penn.NEWS4: Conatus Down More Than 60% in the Past 90 Days: Here's Why.NEWS5: Market Morning: Huawei Fumes, Volkswagen Feuds, Novartis Wins, Farage Threatens.NEWS6: A Closer Look at Vanguard Global ESG Select Stock.
2019-05-29: NEWS1: The Only 3 Marijuana Stocks You Need to Own.NEWS2: The Only 3 Marijuana Stocks You Need to Own.NEWS3: The Only 3 Marijuana Stocks You Need to Own.
2019-05-30: NEWS1: Save the Date: 11 Biotech Stocks to Put on Your Radar.NEWS2: PDL BioPharma's Royalties Help, Heavy Partner Reliance Hurts.NEWS3: PDL BioPharma's Royalties Help, Heavy Partner Reliance Hurts.NEWS4: PDL BioPharma's Royalties Help, Heavy Partner Reliance Hurts.NEWS5: Bothered by the Price Tag of a $2.1 Million Drug? Read This Before Complaining Too Much.NEWS6: Bothered by the Price Tag of a $2.1 Million Drug? Read This Before Complaining Too Much.NEWS7: Health Care Sector Update for 05/30/2019: UBX, ACHV, NVS, JNJ, PFE, ABT, MRK, AMGN.NEWS8: Health Care Sector Update for 05/30/2019: UBX, ACHV, NVS, JNJ, PFE, ABT, MRK, AMGN.NEWS9: Bothered by the Price Tag of a $2.1 Million Drug? Read This Before Complaining Too Much.NEWS10: The Daily Biotech Pulse: Unity Biotech Licenses Anti-Aging Protein, Strong Results For Mereo's Brittle Bone Disease Drug.
2019-05-31: NEWS1: Attention Biotech Investors: Mark Your Calendar For These June PDUFA Dates.NEWS2: Nationwide Children's invented 'the most expensive drug ever,' but the hospital didn't set the price.NEWS3: FDA approval of life-saving Nationwide Children's invention bodes well for ongoing gene therapy research.NEWS4: Is the $2.1 Million Price Tag for Novartis' Zolgensma Ridiculous?.NEWS5: Is the $2.1 Million Price Tag for Novartis' Zolgensma Ridiculous?.NEWS6: Biogen Reports Interim Phase III Data on Diroximel Fumarate.NEWS7: Biogen Reports Interim Phase III Data on Diroximel Fumarate.NEWS8: Is the $2.1 Million Price Tag for Novartis&apos; Zolgensma Ridiculous?.NEWS9: Biogen Reports Interim Phase III Data on Diroximel Fumarate.NEWS10: Novartis (NVS) Reports Positive Phase III Data on Asthma Drug.NEWS11: Novartis (NVS) Reports Positive Phase III Data on Asthma Drug.NEWS12: Novartis (NVS) Reports Positive Phase III Data on Asthma Drug.

Answer: Rise